Form 4: ImmuCell Director Kathy Turner Receives Stock Options

Director Kathy V. Turner was granted 17,899 non-qualified stock options as compensation for board service.

Summary

• Director Kathy V. Turner received a grant of 17,899 non-qualified stock options on April 15, 2026.
• The options have an exercise price of $7.60 per share.
• The grant is part of the standard compensation package for ImmuCell Corporation board members.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in minor potential dilution for existing shareholders upon future exercise of options.

Risks

• Market price volatility may impact the future value of the granted options.

Future Outlook

The options vest in three equal installments over the next three years, indicating a long-term commitment to the company.

Management Comments

• The options were granted by the issuer to compensate directors for services on the Issuer's board of directors.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard corporate governance practice in the biotechnology sector to ensure alignment between leadership and shareholders.

Comparison to Industry Standards

• The use of multi-year vesting schedules for director options is consistent with standard corporate governance practices for small-cap biotech firms.

Stakeholder Impact

• Shareholders: Minor dilution impact upon exercise.
• Director: Increased equity stake in the company.

Next Steps

• Vesting of 5,966 shares on April 15, 2027.
• Vesting of 5,966 shares on April 15, 2028.
• Vesting of 5,967 shares on April 15, 2029.

Key Dates

Keywords

ImmuCell, ICCC, Director Compensation, Stock Options, Insider Transaction, Form 4